Newsletter · 2026-07-27 · Ashutosh Agarwal

Novo Sues Lilly Over Obesity Ad as Durability Becomes the Real Battle - The GLP-1 Complex - Week of July 20, 2026

Novo Nordisk takes Eli Lilly to court over a Zepbound-versus-Wegovy ad while trial data, employers, and telehealth reshape the obesity-drug fight, for the week of July 20, 2026.

The GLP-1 Complex

Week of July 20, 2026: Novo Sues Lilly Over Obesity Ad as Durability Becomes the Real Battle

The obesity-drug fight left the lab this week and walked into a courtroom. Novo Nordisk sued Eli Lilly over a television ad that makes Lilly's Zepbound look like it crushes Novo's Wegovy on weight loss. Novo says the comparison is a magic trick: Lilly is measuring its best drug against an old, weaker version of Wegovy. The suit is really a proxy for the bigger story of the year, which is that Lilly took the market Novo invented, and Novo now has a new, more aggressive CEO who is done playing nice.

TL;DR

• Novo is suing Lilly in federal court in New Jersey, arguing a heavily aired ad ("50 pounds vs 33 pounds") compares Zepbound to an outdated low dose of Wegovy, not the new high-dose version that loses about the same amount.
• The real battleground is durability. Fresh trial data and a device startup both hammered the same point: most people quit these drugs and gain the weight back, and whoever solves that owns the next chapter.
• Employers are quietly pulling back, not leaning in. A new survey found 19% of employers who once covered these drugs for weight loss have dropped that coverage, as the drugs eat 11%-plus of their total health claims.

What's New

Novo took Lilly to court over its most-watched ad. On the July 22 Morning Brew Daily, the hosts laid out the fight in plain terms. Lilly's ad cites a head-to-head trial where Zepbound patients lost an average of 50 pounds versus 33 for Wegovy. The catch: that 33-pound number is from the older 2.4mg Wegovy. Novo this year launched a stronger 7.2mg dose that lost about 47 pounds in its own study, which is almost neck-and-neck. Novo says the ad has racked up 700 million impressions since late April, calls Lilly's tiny on-screen disclaimer "ambiguous, confusing, virtually illegible," and wants a court to pull the ad. Lilly's defense, echoed on the July 22 The Rundown: head-to-head trials are the gold standard, and there is no head-to-head trial pitting the newest Wegovy against Zepbound, so it is using the best evidence it has. Why this matters for the numbers: The Rundown host noted Lilly stock is up about 50% over the past year while Novo is down 24%. This lawsuit is what losing the lead looks like.

Jim Cramer told viewers to buy Lilly into the dip. On the July 21 Squawk on the Street, with Lilly down about 7% on the news, Cramer called the suit "not a big deal" and said Lilly's ad is quoting the New England Journal of Medicine, which he trusts. His advice to Novo: "prove it" with your own head-to-head. His bigger point was about muscle, not marketing: "In the end, it's about infrastructure. Lilly's got better infrastructure," and Novo doesn't have the manufacturing budget to match. (This is pundit commentary, not company guidance, but Cramer moves retail flows.)

A new CEO is remaking Novo in Lilly's image. On the July 23 The Readout Loud from STAT, reporter Elaine explained that new Novo chief Mike Doustdar has "made Novo kind of more similar to Lilly," leaning hard into telehealth and now suing. That aggression cuts both ways. The same episode covered STAT's investigation into LifeMD, a publicly traded telehealth company that Novo lists on its own website and ties to an exclusive Wegovy subscription. On the July 22 On The Pen GLP-1 News, the host walked through the allegations: clinicians pushed to review roughly 25 patient cases an hour (one every two and a half minutes), appointments trimmed toward an average of about seven minutes, and a former chief operating officer who says he was prescribed six different GLP-1s and dropped from 286 to 177 pounds in under a year before developing a serious ear disorder. LifeMD denies all of it. The read-through: the telehealth pipes that Novo and Lilly now depend on to reach patients are also a regulatory and headline risk they don't fully control.

Lilly put a date on its next mega-drug, and it's later than the Street hoped. On the July 23 Bloomberg Intelligence, Bloomberg reporter Madison Muller said Lilly will file retatrutide for FDA approval in the first quarter of 2027, "a little bit later than some analysts had expected," because the data package is so large. Retatrutide is the "triple" drug (it hits three gut hormones instead of one or two) and has shown up to about 30% weight loss, bariatric-surgery territory. She also flagged the pricing shift that quietly reshapes the whole market: cash-pay prices have fallen from more than $1,000 a month to roughly $200, though insurance still doesn't broadly cover these drugs.

The Debate

The bull case (voiced loudest by pundits): Lilly is a runaway train. On the July 23 Full Signal, investor Michael of the Lead-Lag Report called Lilly "the NVIDIA of the health care space" and predicted retatrutide could be "the first trillion-dollar drug," partly because it also nudges up your resting metabolism, so you eat less and burn more. He owns the stock and thinks Lilly keeps winning, then goes on an acquisition spree (it recently bought atai, on the psychedelics side) as obesity drugs shrink the market for other ailments. Treat this as enthusiasm, not analysis, but it captures the mood: this is a category people expect to just keep compounding.

The bear case is quieter and more interesting, it's about durability and payers, not competition. Two credible, on-the-ground voices made the same argument from different angles. On the July 24 DeviceTalks, Fractyl Health CEO Harith Rajagopalan, whose company is building an endoscopic procedure to help people keep weight off after they stop the drugs, said the quiet part out loud: "Most people stop taking these medicines within 6 to 12 months," and when they do, "they regain all of their weight." He estimates about one million Americans a month stop a GLP-1 and regain almost all the weight over the following 12 to 18 months, calling it "the largest orphan disease you could possibly imagine." Tellingly, he says payers want obesity treated but do not want "a lifetime payment stream to the GLP-1 manufacturers." That is the whole bear thesis in one sentence: if people don't stay on the drugs, the lifetime-revenue math gets shakier.

The EMARKETER data backs the durability worry. On the July 22 Behind the Numbers, healthcare analyst Rajiv Leventhal said only about one-third of GLP-1 patients are still on their medication roughly 13 months in. The market is real and huge (he pegs current use at about 12% to 15% of the US population, tens of millions of people) but it's a revolving door, not a locked-in subscription.

Read-throughs

Maintenance is becoming its own product category, good for pills, complicated for injectables. The most important clinical read of the week was the ATTAIN-MAINTAIN trial, covered on the July 20 Back on Track by Dr. Alicia Shelly and again on the July 21 Decera Clinical Education panel. The study took people who had already lost weight on Lilly's Zepbound (tirzepatide) or Novo's Wegovy (semaglutide) and switched them to Lilly's once-a-day oral pill orforglipron. Those coming off Zepbound kept about 75% of their lost weight versus 49% on placebo; those coming off Wegovy kept about 79% versus 38%. In plain terms: a cheap daily pill may be enough to hold the line after an expensive injection does the heavy lifting. That's a strategic win for Lilly's oral franchise and a real threat to the "inject forever" revenue model.

The device angle is now investable. Fractyl (ticker GUTS) said its post-drug maintenance trial enrolled 20 to 50 times faster than its old diabetes trial, with pivotal data due early in the fourth quarter. It's a razor-and-blades model, a disposable catheter plus a console. Whether or not Fractyl specifically wins, the DeviceTalks conversation is a flare: medtech now sees "life after GLP-1" as a market worth chasing.

Retail and consumer names should stop treating GLP-1 users as one static group. The EMARKETER team's sharpest point was that these patients are fluid, some losing, some maintaining, some cycling off and regaining, and they eat less but trade up, buying more fresh produce and dining out more socially. The messier read-through is returns: shoppers whose sizes keep changing are flooding apparel retailers with returns and feeding the resale market. Watch it show up in packaged food and apparel commentary (Nestle already runs a GLP-1-friendly product site; Walmart and ShopRite have added in-pharmacy nutrition support for these customers).

Fast-follower reality check. On the July 21 Diabetes Connections, host Stacey Simms reported Roche walked away from its GLP-1 candidate acmopatide for type 1 diabetes, "a business decision," even after decent results, a reminder that not every entrant sticks around. And on the July 22 Biotech 2050, Sparrow Pharmaceuticals CEO Robert Jacks said he refuses to be "the thousandth incretin receptor agonist," arguing the GLP-1 class is on "the backside of the innovation curve" and that roughly half of type 2 diabetics still aren't well controlled, a pitch that the easy wins in this space may be behind us.

The plumbing: pricing pressure at the pharmacy counter. On the July 24 Pharmacy Podcast Network, independent pharmacy owner Tom DiPietro of Scranton said he has filled more than 600 GLP-1 prescriptions through a GoodRx cash program at a $149 price point. His blunt admission, that on a normal GLP-1 script he might "make five bucks, maybe lose 30," shows how brutal the economics are for the middle of the supply chain even as the drugmakers thrive.

The Payers

This is the number that should worry the bulls. On the July 22 Talking Benefits, the International Foundation of Employee Benefit Plans walked through a survey of more than 300 US employers taken in early June. The headline: 60% cover these drugs for diabetes only, just 36% cover them for weight loss, and, the striking one, 19% previously covered weight loss and have since dropped it. Only 9% are actively considering adding coverage. Among employers who do cover the drugs for weight loss, they now eat an average of 11.4% of total health claims (up from 10.5% a year earlier), and a quarter of those employers say the drugs are more than 15% of all claims. Nearly all (95%) require prior authorization. This is the counterweight to every "everyone will be on these forever" take: the people who actually pay the bills are tightening, not loosening.

There is a partial offset on the government side. Both Diabetes Connections and the Fractyl interview noted the new Medicare GLP-1 "bridge" program, live since July 1, which gives eligible Part D patients an easier path to Wegovy, Zepbound, and Lilly's oral Foundeo. More covered lives at the top, more employer carve-outs underneath, the coverage map is getting more lopsided, not simpler.

One for the Long View

If you want the reminder of why this franchise exists at all, the July 20 The Heart of Healthcare with author Eric Ries is worth twenty minutes. He tells the story of how Novo's foundation trustees blocked a late-1990s merger that would have shut down a then-13-year, fruitless research program, the program that eventually became Ozempic and Wegovy, "the most profitable drugs in the history of pharmaceuticals," and, he estimates, more than $500 billion of shareholder value. There was a point where Novo's market cap exceeded the entire GDP of Denmark. The whole current war (the ads, the lawsuit, the trillion-dollar talk) traces back to one boardroom that refused to sell too early.